Insider Transactions in Q1 2022 at Chinook Therapeutics, Inc. (KDNY)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-29.77%
|
$32,500
$13.0 P/Share
|
|
Feb 11
2022
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,735
-2.64%
|
$44,820
$12.74 P/Share
|
|
Feb 11
2022
|
Alan Glicklich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,391
-23.25%
|
$28,692
$12.74 P/Share
|
|
Feb 11
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,498
-22.93%
|
$29,976
$12.74 P/Share
|
|
Feb 11
2022
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
895
-3.87%
|
$10,740
$12.74 P/Share
|
|
Feb 10
2022
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,801
+4.59%
|
-
|
|
Feb 10
2022
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,247
+9.16%
|
-
|
|
Feb 10
2022
|
Alan Glicklich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,668
+35.54%
|
-
|
|
Feb 10
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,301
+32.96%
|
$0
$0.35 P/Share
|
|
Feb 10
2022
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,434
+9.53%
|
-
|
|
Feb 10
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-37.91%
|
$32,500
$13.31 P/Share
|
|
Jan 03
2022
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-14.23%
|
$16,000,000
$16.0 P/Share
|
|
Jan 03
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-14.23%
|
$6,400,000
$16.0 P/Share
|
|
Jan 03
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
600,000
-14.21%
|
$9,600,000
$16.0 P/Share
|